ID: ALA454606

Max Phase: Preclinical

Molecular Formula: C14H12N2O2

Molecular Weight: 240.26

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCOC(=O)c1cc2c(cn1)[nH]c1ccccc12

Standard InChI:  InChI=1S/C14H12N2O2/c1-2-18-14(17)12-7-10-9-5-3-4-6-11(9)16-13(10)8-15-12/h3-8,16H,2H2,1H3

Standard InChI Key:  KOVRZNUMIKACTB-UHFFFAOYSA-N

Associated Targets(Human)

HL-60 67320 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A498 42825 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

COLO 205 50209 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

SK-OV-3 52876 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Detroit 551 346 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Phosphodiesterase 5A 5113 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA-A receptor; anion channel 986 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-1 subunit 399 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-2 subunit 271 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-3 subunit 187 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-4 subunit 15 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-5 subunit 699 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

GABA receptor alpha-6 subunit 26 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 240.26Molecular Weight (Monoisotopic): 240.0899AlogP: 2.89#Rotatable Bonds: 2
Polar Surface Area: 54.98Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.01CX Basic pKa: 2.10CX LogP: 2.42CX LogD: 2.42
Aromatic Rings: 3Heavy Atoms: 18QED Weighted: 0.70Np Likeness Score: -0.26

References

1. Neaz MM, Muddassar M, Pasha FA, Cho SJ.  (2009)  2D-QSAR of non-benzodiazepines to benzodiazepines receptor (BZR),  18  (2): [10.1007/s00044-008-9111-6]
2. Chen YF, Lin YC, Chen JP, Chan HC, Hsu MH, Lin HY, Kuo SC, Huang LJ..  (2015)  Synthesis and biological evaluation of novel 3,9-substituted β-carboline derivatives as anticancer agents.,  25  (18): [PMID:26235951] [10.1016/j.bmcl.2015.07.058]
3. Cappelli A, Anzini M, Castriconi F, Grisci G, Paolino M, Braile C, Valenti S, Giuliani G, Vomero S, Di Capua A, Betti L, Giannaccini G, Lucacchini A, Ghelardini C, Di Cesare Mannelli L, Frosini M, Ricci L, Giorgi G, Mascia MP, Biggio G..  (2016)  Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.,  59  (7): [PMID:26982523] [10.1021/acs.jmedchem.6b00034]
4. Young RJ, Leeson PD..  (2018)  Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.,  61  (15): [PMID:29620890] [10.1021/acs.jmedchem.8b00180]
5. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source